INS and Hypoglycemia: In a prior meta-analysis, there was no difference in hypoglycemia risk between treatment with SGLT2 inhibitors plus insulin therapy and that with placebo (OR 1.18, 95% CI 0.86–1.61, p = 0.30) (7).